DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

Background and aims Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis. Design We analysed DYRK1A expression in PDAC genetic mouse models and in patient samples. DYRK1A function was assessed with knockdown experiments in pancreatic tumour cell lines and in PDAC mouse models with genetic reduction of Dyrk1a dosage. Furthermore, we explored a mechanistic model for DYRK1A activity. Results We showed that DYRK1A was highly expressed in PDAC, and that its protein level positively correlated with that of c-MET. Inhibition of DYRK1A reduced tumour progression by limiting tumour cell proliferation. DYRK1A stabilised the c-MET receptor through SPRY2, leading to prolonged activation of extracellular signal-regulated kinase signalling. Conclusions These findings reveal that DYRK1A contributes to tumour growth in PDAC, at least through regulation of c-MET accumulation, suggesting that inhibition of DYRK1A could represent a novel therapeutic target for PDAC.

[1]  S. de la Luna,et al.  DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells. , 2018, Cell reports.

[2]  Sam J. Mathew,et al.  SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma , 2018, Cell Death & Disease.

[3]  M. Salto‐Tellez,et al.  Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges , 2017, Nature Reviews Clinical Oncology.

[4]  Hyori Kim,et al.  Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy , 2017, Experimental & Molecular Medicine.

[5]  Nandini A. Sahasrabuddhe,et al.  A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma , 2016, Scientific Reports.

[6]  L. Rosen,et al.  A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer , 2016, Clinical Cancer Research.

[7]  A. Schetter,et al.  A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. , 2016, Cancer research.

[8]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[9]  Jingwu Xie,et al.  Deciphering the role of hedgehog signaling in pancreatic cancer , 2016, Journal of biomedical research.

[10]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[11]  Jianmin Wu,et al.  The kinome 'at large' in cancer , 2016, Nature Reviews Cancer.

[12]  A. Califano,et al.  An ID2-dependent mechanism for VHL inactivation in cancer , 2015, Nature.

[13]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[14]  Nicolas Stransky,et al.  Targeting cancer with kinase inhibitors. , 2015, The Journal of clinical investigation.

[15]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[16]  L. Trusolino,et al.  Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs. , 2014, Cancer research.

[17]  Ying Tang,et al.  LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth , 2014, Clinical Cancer Research.

[18]  Qiang Liu,et al.  Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-Myc , 2014, PloS one.

[19]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[20]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[21]  M. Hagiwara,et al.  Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth. , 2013, The Journal of clinical investigation.

[22]  J. Kissil,et al.  Notch signaling in pancreatic cancer: oncogene or tumor suppressor? , 2013, Trends in molecular medicine.

[23]  W. Becker.  Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control , 2012, Cell cycle.

[24]  M. Barbacid,et al.  EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. , 2012, Cancer Cell.

[25]  J. Crispino,et al.  Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome. , 2012, The Journal of clinical investigation.

[26]  A. Drach‐Zahavy,et al.  Control , 2012, Qualitative health research.

[27]  P. Yin,et al.  The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer , 2011, International journal of oncology.

[28]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[29]  A. Siriwardena,et al.  Epidermal Growth Factor Receptor in Pancreatic Cancer , 2011, Cancers.

[30]  A. Laguna,et al.  DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  I. Fariñas,et al.  Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. , 2010, Cell stem cell.

[32]  D. Calvisi,et al.  Synergistic role of sprouty2 inactivation and c‐Met up‐regulation in mouse and human hepatocarcinogenesis , 2010, Hepatology.

[33]  M. Bissonnette,et al.  Sprouty-2 Controls c-Met Expression and Metastatic Potential of Colon Cancer Cells: Sprouty/c-Met Upregulation in Human Colonic Adenocarcinomas , 2010, Oncogene.

[34]  W. Becker,et al.  Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation , 2009, The FEBS journal.

[35]  M. Nieto,et al.  Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A , 2009, Journal of Cell Science.

[36]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[37]  S. Aranda,et al.  Sprouty2-Mediated Inhibition of Fibroblast Growth Factor Signaling Is Modulated by the Protein Kinase DYRK1A , 2008, Molecular and Cellular Biology.

[38]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[39]  S. Landas,et al.  The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma. , 2005, Cancer research.

[40]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[41]  G. Woude,et al.  Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis , 2004, Oncogene.

[42]  Dianqing Wu,et al.  Regulation of Gli1 Transcriptional Activity in the Nucleus by Dyrk1* , 2002, The Journal of Biological Chemistry.

[43]  X. Estivill,et al.  Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice , 2002, Molecular and Cellular Biology.

[44]  H. Band,et al.  Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. , 2001, Molecular cell.

[45]  M. Tsao,et al.  Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. , 1995, The American journal of pathology.

[46]  H. Friess,et al.  Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. , 1994, Cancer research.

[47]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[48]  J. Licht,et al.  Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. , 2006, Trends in cell biology.

[49]  R. Palmiter,et al.  Pancreatic tumor pathogenesis reflects the causative genetic lesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.